Nature Chemical Biology 2006-06-01

Identifying off-target effects and hidden phenotypes of drugs in human cells.

Marnie L MacDonald, Jane Lamerdin, Stephen Owens, Brigitte H Keon, Graham K Bilter, Zhidi Shang, Zhengping Huang, Helen Yu, Jennifer Dias, Tomoe Minami, Stephen W Michnick, John K Westwick

Index: Nat. Chem. Biol. 2 , 329-37, (2006)

Full Text: HTML

Abstract

We present a strategy for identifying off-target effects and hidden phenotypes of drugs by directly probing biochemical pathways that underlie therapeutic or toxic mechanisms in intact, living cells. High-content protein-fragment complementation assays (PCAs) were constructed with synthetic fragments of a mutant fluorescent protein ('Venus', EYFP or both), allowing us to measure spatial and temporal changes in protein complexes in response to drugs that activate or inhibit particular pathways. One hundred and seven different drugs from six therapeutic areas were screened against 49 different PCA reporters for ten cellular processes. This strategy reproduced known structure-function relationships and also predicted 'hidden,' potent antiproliferative activities for four drugs with novel mechanisms of action, including disruption of mitochondrial membrane potential. A simple algorithm identified a 25-assay panel that was highly predictive of antiproliferative activity, and the predictive power of this approach was confirmed with cross-validation tests. This study suggests a strategy for therapeutic discovery that identifies novel, unpredicted mechanisms of drug action and thereby enhances the productivity of drug-discovery research.